Vascular Ultrasound Analysis Workstation

描述(申请人提供)：血管形态或细小改变 功能提示心血管疾病的早期阶段导致 冠心病和中风。电脑化方法的发展 内皮功能、内膜-中层的定量无创评估 厚度和顺应性对心血管疾病的早期评估很重要 疾病。 在第一阶段，我们开发并验证了直径的计算机化方法 臂部超声图像序列的测量及其应用 准确定量血管内皮细胞功能的可行性。这是第二阶段 提案扩展了第一阶段所做的工作，以开发一个综合工具 以便及早发现动脉粥样硬化。 第二阶段的具体目标是： 1.开发实用、准确、高度自动化的算法和方法 评估血管血流介导的血管扩张、内膜-中层厚度和 合规性。 2.开发血管超声分析工作站，将允许 对血管尺寸和功能进行用户友好的评估。 3.以标准化的方式评价工作站的准确性和重复性 图像数据。这将使大量人口、制药和 临床研究。 开发的工具将有可能识别符合以下条件的受试者 注定要患动脉粥样硬化性闭塞性血管疾病。最终的产品将是 以软件包或集成交钥匙计算机站的形式提供。 建议的商业应用： 我们预计我们的第二阶段研究工作的成果将以类似的方式商业化 时尚作为第一阶段的结果。一个商业化的第二阶段软件包将会找到 它在心血管研究人员流行病学研究中的应用 研究人员和制药行业进行药物相关试验，临床医生进行常规 通过测量内膜-中层厚度评估卒中风险。我们还设想 开发的软件将被超声波制造商采用并成为 血管超声机的组成部分。

DESCRIPTION (Provided by Applicant):Small changes of vascular morphology or function are indicative of early stages of cardiovascular disease leading to coronary heart disease and stroke. Development of computerized methods for quantitative non-invasive assessment of the endothelial function, intima-media thickness, and compliance is important for early assessment of cardiovascular disease. During Phase I, we developed and validated a computerized method for diameter measurement in brachial ultrasound image sequences and demonstrated its feasibility for accurate quantitation of endothelial function. This Phase II proposal expands on the work done in Phase I to develop a comprehensive tool for early detection of atherosclerosis. The specific aims of Phase II are to: 1. Develop algorithms and methods for practical, accurate, and highly automated assessment of vascular flow-mediated vasodilation, intima-media thickness, and compliance. 2. Develop a Vascular Ultrasound Analysis Workstation that will allow user-friendly assessment of vascular dimensions and function. 3. Evaluate the accuracy and reproducibility of the workstation in standardized image data. This will allow employment in large population, pharmaceutical, and clinical studies. The developed tool will have the potential to identify subjects who are destined for atherosclerotic occlusive vascular disease. The final product will be available as a software package or an integrated turn-key computer station. PROPOSED COMMERCIAL APPLICATIONS: We expect that results of our Phase II research work will be commercialized in a similar fashion as the Phase I outcome. A commercialized Phase II software package will find its application among cardiovascular researchers for epidemiologic studies, cardiovascular researchers and pharmaceutical industry for drug-related trials, and clinicians for routine assessment of stroke risk via measurement of intima-media thickness. We also envision that developed software will be adopted by ultrasound manufacturers and become integral part of vascular ultrasound machines.